{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:09:36Z","timestamp":1789978176692,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04326-x","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:40:59Z","timestamp":1762962059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm"],"prefix":"10.1186","volume":"25","author":[{"given":"Giuseppe","family":"Romano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Lus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"11\u201312","key":"4326_CR1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1177\/13524585231199819","volume":"29","author":"Y Wu","year":"2023","unstructured":"Wu Y, Geraldes R, Jury\u0144czyk M, Palace J. Double-negative neuromyelitis optica spectrum disorder. Mult Scler. 2023;29(11\u201312):1353\u201362.","journal-title":"Mult Scler"},{"issue":"4","key":"4326_CR2","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","volume":"1","author":"S Ramanathan","year":"2014","unstructured":"Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014;1(4):e40.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"4326_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71(3):276\u201383.","journal-title":"JAMA Neurol"},{"issue":"21","key":"4326_CR4","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","volume":"90","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology. 2018;90(21):e1858\u201369.","journal-title":"Neurology"},{"issue":"Suppl. 3","key":"4326_CR5","first-page":"93","volume":"22","author":"L Pandit","year":"2016","unstructured":"Pandit L, Sato D, Siritho S, et al. Characterization of seronegative neuromyelitis optica in 2016. Mult Scler. 2016;22(Suppl. 3):93.","journal-title":"Mult Scler"},{"issue":"6","key":"4326_CR6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474\u201381.","journal-title":"Neurology"},{"issue":"6","key":"4326_CR7","doi-asserted-by":"publisher","first-page":"e607","DOI":"10.1212\/NXI.0000000000000607","volume":"6","author":"M Sepulveda","year":"2019","unstructured":"Sepulveda M, Delgado-Garc\u00eda G, Blanco Y, et al. Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e607.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"4326_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00415-021-10619-1","volume":"269","author":"M Jury\u0144czyk","year":"2022","unstructured":"Jury\u0144czyk M, Klimiec-Moskal E, Kong Y, et al. Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis. J Neurol. 2022;269(1):269\u201379.","journal-title":"J Neurol"},{"issue":"12","key":"4326_CR9","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","volume":"256","author":"A Uzawa","year":"2009","unstructured":"Uzawa A, Mori M, Ito M, et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol. 2009;256(12):2082\u20134.","journal-title":"J Neurol"},{"issue":"5","key":"4326_CR10","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","volume":"7","author":"K Fujihara","year":"2020","unstructured":"Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D, Mughal T, Yamamura T. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e841.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"4326_CR11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.pneurobio.2011.01.005","volume":"93","author":"J Middeldorp","year":"2011","unstructured":"Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011;93(3):421\u201343. https:\/\/doi.org\/10.1016\/j.pneurobio.2011.01.005.","journal-title":"Prog Neurobiol"},{"issue":"2","key":"4326_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1152\/physrev.00024.2003","volume":"84","author":"J Avila","year":"2004","unstructured":"Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004;84(2):361\u201384. https:\/\/doi.org\/10.1152\/physrev.00024.2003.","journal-title":"Physiol Rev"},{"issue":"1","key":"4326_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12974-022-02450-w","volume":"19","author":"JW Hyun","year":"2022","unstructured":"Hyun JW, Kim Y, Kim KH, Kim SH, Olesen MN, Asgari N, Siritho S, Paul F, Kim HJ. CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage. J Neuroinflammation. 2022;19(1):86.","journal-title":"J Neuroinflammation."},{"issue":"3","key":"4326_CR14","doi-asserted-by":"publisher","first-page":"e708","DOI":"10.1212\/NXI.0000000000000708","volume":"7","author":"H Kim","year":"2020","unstructured":"Kim H, Lee EJ, Kim S, Choi LK, Kim K, Kim HW, Kim KK, Lim YM. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e708.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"4326_CR15","doi-asserted-by":"publisher","first-page":"e200188","DOI":"10.1212\/NXI.0000000000200188","volume":"11","author":"S Carta","year":"2024","unstructured":"Carta S, Dinoto A, Capobianco M, Valentino P, Montarolo F, Sala A, Reindl M, Lo Re M, Chiodega V, Branger P, Audoin B, Aboab J, Papeix C, Collongues N, Kerschen P, Zephir H, Cr\u00e9ange A, Bourre B, Schanda K, Flanagan EP, Redenbaugh V, Villacieros-\u00c1lvarez J, Arrambide G, Cobo-Calvo A, Ferrari S, Marignier R, Mariotto S. Serum biomarker profiles discriminate AQP4 seropositive and double seronegative neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2024;11(1):e200188.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"22","key":"4326_CR16","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J. Trial of Satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114\u201324.","journal-title":"N Engl J Med"},{"issue":"5","key":"4326_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402\u201312.","journal-title":"Lancet Neurol"},{"issue":"1","key":"4326_CR18","doi-asserted-by":"publisher","first-page":"e1100","DOI":"10.1212\/NXI.0000000000001100","volume":"9","author":"M Ringelstein","year":"2021","unstructured":"Ringelstein M, Ayzenberg I, Lindenblatt G, Fischer K, Gahlen A, Novi G, Hayward-K\u00f6nnecke H, Schippling S, Rommer PS, Kornek B, Zrzavy T, Biotti D, Ciron J, Audoin B, Berthele A, Giglhuber K, Zephir H, K\u00fcmpfel T, Berger R, R\u00f6ther J, H\u00e4u\u00dfler V, Stellmann JP, Whittam D, Jacob A, Kraemer M, Gueguen A, Deschamps R, Bayas A, H\u00fcmmert MW, Trebst C, Haarmann A, Jarius S, Wildemann B, Grothe M, Siebert N, Ruprecht K, Paul F, Collongues N, Marignier R, Levy M, Karenfort M, Deppe M, Albrecht P, Hellwig K, Gold R, Hartung HP, Meuth SG, Kleiter I, Aktas O, Neuromyelitis Optica Study Group (NEMOS). Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):e1100.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4326_CR19","doi-asserted-by":"publisher","unstructured":"Reindl M, Schanda K, Woodhall M, Tea F, Ramanathan S, Sagen J, Fryer JP, Mills J, Teegen B, Mindorf S, Ritter N, Krummrei U, St\u00f6cker W, Eggert J, Flanagan EP, Ramberger M, Hegen H, Rostasy K, Berger T, Leite MI, Palace J, Irani SR, Dale RC, Probst C, Probst M, Brilot F, Pittock SJ, Waters P. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm. 2020;7(2):e674. https:\/\/doi.org\/10.1212\/NXI.0000000000000674. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e718.","DOI":"10.1212\/NXI.0000000000000674"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04326-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04326-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04326-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:41:00Z","timestamp":1762962060000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04326-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4326"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04326-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not applicable to this study. Written informed consent was obtained from the patient for the publication of this case.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of this case report, including clinical details and images, was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"465"}}